文献速递糖尿病肥胖与代谢综合征

2型糖尿病与癌症关联的荟萃分析及未测量混杂偏倚分析

Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People.
PubMed 文献 · Diabetes Care · 2020-01-01

结果强烈提示T2D与肝癌、胰腺癌、子宫内膜癌发病率及胰腺癌死亡率存在因果关联,而与其他癌症的关联对未测量混杂不够稳健。

要点

  • T2D与肝癌、胰腺癌、子宫内膜癌发病率及胰腺癌死亡率关联稳健,强烈提示因果。
  • T2D与前列腺癌风险降低相关(RR 0.83;95% CI 0.79, 0.88)。
  • 其他癌症关联在未测量混杂下稳健性不足,需谨慎解读。

核心结论

  • 研究强烈提示T2D与肝癌、胰腺癌、子宫内膜癌发病率及胰腺癌死亡率存在因果关联。
  • T2D与其他癌症的关联对未测量混杂不够稳健。

研究设计与样本

  • 系统检索PubMed、Web of Science和Cochrane library(2019年1月10日)的观察性研究。
  • 提取队列水平相对风险(RR),采用随机效应荟萃分析和偏倚分析。

主要发现

  • T2D与前列腺癌发病率负相关(RR 0.83;95% CI 0.79, 0.88)。
  • T2D与肝癌发病率正相关(RR 2.23;95% CI 1.99, 2.49)。
  • T2D与胰腺癌死亡率正相关(RR 1.67;95% CI 1.30, 2.14)。

关键数值与推荐

  • 偏倚分析假设未测量混杂与T2D和癌症的RR均为1.5时,真实效应大于RR 1.1的研究比例:肝癌、胰腺癌、子宫内膜癌近100%,胆囊癌86%,肾癌67%,结肠癌64%,结直肠癌62%,其他癌症发病率<50%,胰腺癌死亡率92%。

临床怎么用

  • 对T2D患者应重视肝癌、胰腺癌、子宫内膜癌的筛查与监测。
  • 胰腺癌死亡率风险升高提示T2D患者需关注胰腺癌相关死亡风险。
  • 其他癌症关联证据不够稳健,临床决策需结合个体情况。

局限性

  • 未对除未测量混杂外的其他偏倚进行定量评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Whether the association between type 2 diabetes (T2D) and cancer is causal remains controversial. The goal of this work is to assess the robustness of the observational associations between T2D and cancer to unmeasured confounding. DATA SOURCES AND STUDY SELECTION: PubMed, Web of Science, and the Cochrane library were systematically searched on 10 January 2019 for observational studies investigating associations between T2D and cancer incidence or mortality. DATA EXTRACTION AND DATA SYNTHESIS: Cohort-level relative risk (RR) was extracted. RRs were combined in random-effects meta-analyses and pooled estimates used in bias analyses. A total of 151 cohorts (over 32 million people, 1.1 million cancer cases, and 150,000 cancer deaths) were included. In meta-analyses, T2D was associated with incidence of several cancers, from prostate (RR 0.83; 95% CI 0.79, 0.88) to liver (2.23; 1.99, 2.49), and with mortality from pancreatic cancer (1.67; 1.30, 2.14). In bias analyses, assuming an unmeasured confounding associated with both T2D and cancer with a RR of 1.5, the proportion of studies with a true effect size larger than a RR of 1.1 (i.e., 10% increased risk in individuals with T2D) was nearly 100% for liver, pancreatic, and endometrial, 86% for gallbladder, 67% for kidney, 64% for colon, 62% for colorectal, and <50% for other cancer incidences, and 92% for pancreatic cancer mortality. LIMITATIONS: Biases other than unmeasured confounding were not analytically assessed. CONCLUSIONS: Our findings strongly suggest a causal association between T2D and liver, pancreatic, and endometrial cancer incidence, and pancreatic cancer mortality. Conversely, associations with other cancers were less robust to unmeasured confounding.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ling S, Brown K, Miksza JK, et al. Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care. 2020. PMID: 32910779. doi:10.2337/dc20-0204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。